22nd Century Group is a little biotech developing technology which allows the increase or decrease in the level of nicotine and other nicotinic alkaloids in tobacco plants. The company also has the technology to control levels of cannabinoids in cannabis plants.
The shares have appreciated lately, which is a normal occurrence for a news-driven stock. XXII has an attractive risk-reward profile: its modified risk tobacco product (MRTP) status is the obvious catalyst, as the FDA tightens up the regulation of nicotine levels in cigarettes.
XXII's timing for MRTP is right since the FDA plans to mandate nicotine levels. The drug will open up a lot of commercial opportunities.
www.finstead.com/bit...iction-august-4-2018
The shares have appreciated lately, which is a normal occurrence for a news-driven stock. XXII has an attractive risk-reward profile: its modified risk tobacco product (MRTP) status is the obvious catalyst, as the FDA tightens up the regulation of nicotine levels in cigarettes.
XXII's timing for MRTP is right since the FDA plans to mandate nicotine levels. The drug will open up a lot of commercial opportunities.
www.finstead.com/bit...iction-august-4-2018